BTMD
What one share of biote holds
Medicinal Chemicals and Botanical Products
The business and the industry in which biote Corp. (inclusive of its consolidated subsidiaries,“Biote” “we,” “us,” or “our”) operates is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled “Risk Factors” and elsewhere in this Annual Report.
biote’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.56 |
|---|---|
| Profit | $0.18 |
| Capex (buildings and equipment) | $0.14 |
| Free cash flow | $0.60 |
| Dividends | $0.04 |
| Cash and investments | $0.39 |
| Debt | $4.24 |
| Book value | −$2.30 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $20.47 | −$0.12 | $0.04 | −$1.18 | — | — |
| 2023 | $7.21 | $0.13 | $0.01 | $1.03 | — | −$1.14 |
| 2024 | $5.75 | $0.09 | $0.19 | $1.13 | — | −$3.09 |
| 2025 | $5.24 | $0.74 | $0.14 | $0.82 | — | −$1.87 |